Ovarian stimulation with letrozole, an aromatase inhibitor, results in significantly fewer multiple gestations compared with gonadotropin among couples with unexplained infertility, according to a large-scale randomized trial. However, the rate of multiple gestations was not significantly different between letrozole and clomiphene, researchers report in an article published in the September 24 issue of the New England Journal of Medicine.
Tag: ovarian stimulation
Weight Loss to Improve Fertility Outcomes: How Far Should We Go?
Obesity is now a pandemic and undoubtedly the greatest burden facing health services worldwide. Twenty percent of women of childbearing age are thought to be obese. It is well-established that, in women, obesity is associated with reduced rates of ovulation, increased miscarriage rates and poor response to ovarian stimulation during assisted conception. Male fertility also appears to be similarly adversely affected with evidence of a reduced ejaculate volume, reduced sperm count and increased sperm DNA damage in obese men.
FDA to Review Experimental Fertility Treatment
The Food and Drug Administration has accepted for review Merck & Co. Inc.’s new drug application for an investigational fertility treatment. Merck (NYSE:MRK) is seeking FDA approval of corifollitropin alfa for controlled ovarian stimulation in women participating in assisted reproductive technology.